PHK
RXRX icon

Point72 Hong Kong’s Recursion Pharmaceuticals RXRX Stock Holding History

Point72 Hong Kong’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,987
Closed -$69K – 2319
2021
Q3 		$69K Buy
+2,987
New +$84.7K ﹤0.01% 1443

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Point72 Hong Kong's RXRX Position: Q4 2021 in Review

Point72 Hong Kong sold out of Recursion Pharmaceuticals (RXRX) in Q4 2021, closing a stake of 2,987 shares — an estimated $69K sold.

Point72 Hong Kong first reported a position in RXRX in Q3 2021 and held it in 1 quarter. The position peaked at $69K in Q3 2021. 126 funds tracked by Wall St. Rank hold RXRX as of Q4 2021.

  • Point72 Hong Kong reported no remaining Recursion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 2,987 Recursion Pharmaceuticals shares in Q4 2021, an estimated $69K.
  • Point72 Hong Kong first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Point72 Hong Kong's Recursion Pharmaceuticals position peaked at $69K in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2021.

Based on Point72 Hong Kong's 13F filing for Q4 2021, filed 14 Feb 2022.